Literature DB >> 6849295

A study of optimal reaction conditions for an assay of the human alternative complement pathway.

K A Joiner, A Hawiger, J A Gelfand.   

Abstract

The optimal conditions for performance of a sensitive functional assay for the human alternative complement pathway were studied. The serum dilution causing 50% lysis of rabbit erythrocytes in magnesium EGTA buffer is designated the APH50 titer. Optimal reaction conditions for the assay were pH 7.2, incubation temperature 37 degrees C, incubation time 60 minutes, and magnesium concentration 0.002 M. Lowering the ionic strength of the buffer from 0.150 M to 0.0125 M increased APH50 titers nearly 2.5-fold, but decreased the reproducibility of titers. Significant fluid-phase conversion of C3 at 37 degrees C in low ionic strength buffer was demonstrated by crossed immunoelectrophoresis. Using the optimal reaction conditions, in normal ionic strength buffer the mean APH50 +/- SD for 45 normal adults was 25.3 +/- 5.7 U/mL. Heparin, an inhibitor of the alternative pathway, decreased APH50 by 50% at a concentration of 100 U heparin/mL serum, and totally abolished alternative pathway hemolytic activity at 1,000 U heparin/mL serum, while lowering CH50 titers to a much lesser degree. When increasing doses of zymosan were used for complement activation in vitro, the per cent APH50 depletion at low doses of zymosan was at least twice the per cent depletion of CH50 or antigenic P, B, and C3. A striking dichotomy between nearly complete APH50 depletion and normal or near normal CH50 and hemolytic C4 levels was documented for a human burn patient and for a baboon infused with a lethal dose of Escherichia coli lipopolysaccharide. Therefore, we documented a substantially greater sensitivity of APH50 than of conventional complement determinations for detecting complement consumption by alternative pathway activators.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849295     DOI: 10.1093/ajcp/79.1.65

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

Review 1.  Modern complement analysis.

Authors:  Michael Kirschfink; Tom E Mollnes
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

2.  Early complement components enhance neutralization of Chlamydia trachomatis infectivity by human sera.

Authors:  J S Lin; L L Yan; Y Ho; P A Rice
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

3.  Complement 4 phenotypes and genotypes in Brazilian patients with classical 21-hydroxylase deficiency.

Authors:  G Guerra-Junior; A Sevciovic Grumach; S H Valente de Lemos-Marini; M Kirschfink; A Condino Neto; M de Araujo; M Palandi De Mello
Journal:  Clin Exp Immunol       Date:  2009-02       Impact factor: 4.330

4.  Antibody-independent binding of complement component C1q by Legionella pneumophila.

Authors:  C S Mintz; P I Arnold; W Johnson; D R Schultz
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

5.  Allelic variants of complement genes associated with dense deposit disease.

Authors:  Maria Asuncion Abrera-Abeleda; Carla Nishimura; Kathy Frees; Michael Jones; Tara Maga; Louis M Katz; Yuzhou Zhang; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

6.  Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome.

Authors:  G Zilow; J A Sturm; U Rother; M Kirschfink
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

7.  Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n).

Authors:  P J Späth; A G Sjöholm; G N Fredrikson; G Misiano; R Scherz; U B Schaad; B Uhring-Lambert; G Hauptmann; J Westberg; M Uhlén; C Wadelius; L Truedsson
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

8.  Plasmid-associated resistance of Salmonella typhimurium to complement activated by the classical pathway.

Authors:  J L Vandenbosch; D K Rabert; G W Jones
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

9.  Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Authors:  C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2016-11-25       Impact factor: 4.330

10.  Preferential activation and depletion of the alternative complement pathway by burn injury.

Authors:  J A Gelfand; M Donelan; J F Burke
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.